A detailed history of Jacobs Levy Equity Management, Inc transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 580,783 shares of KOD stock, worth $5.08 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
580,783
Previous 699,158 16.93%
Holding current value
$5.08 Million
Previous $1.64 Million 7.79%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.2 - $3.25 $260,425 - $384,718
-118,375 Reduced 16.93%
580,783 $1.52 Million
Q2 2024

Aug 14, 2024

BUY
$2.29 - $4.48 $397,333 - $777,315
173,508 Added 33.01%
699,158 $1.64 Million
Q1 2024

May 15, 2024

SELL
$3.01 - $7.45 $596,055 - $1.48 Million
-198,025 Reduced 27.36%
525,650 $2.76 Million
Q4 2023

Feb 14, 2024

BUY
$1.4 - $3.24 $659,498 - $1.53 Million
471,070 Added 186.48%
723,675 $2.2 Million
Q3 2023

Nov 16, 2023

SELL
$1.8 - $7.49 $31,557 - $131,314
-17,532 Reduced 6.49%
252,605 $454,000
Q2 2023

Aug 14, 2023

SELL
$4.3 - $9.48 $636,283 - $1.4 Million
-147,973 Reduced 35.39%
270,137 $1.86 Million
Q1 2023

May 15, 2023

BUY
$4.81 - $8.88 $430,504 - $794,777
89,502 Added 27.24%
418,110 $2.59 Million
Q4 2022

Feb 14, 2023

BUY
$6.52 - $8.05 $766,236 - $946,044
117,521 Added 55.67%
328,608 $2.35 Million
Q3 2022

Nov 15, 2022

BUY
$7.57 - $12.5 $1.6 Million - $2.64 Million
211,087 New
211,087 $1.63 Million
Q3 2019

Nov 14, 2019

SELL
$10.24 - $17.57 $106,496 - $182,728
-10,400 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$6.2 - $12.0 $64,480 - $124,800
10,400 New
10,400 $122,000

Others Institutions Holding KOD

About Kodiak Sciences Inc.


  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $455M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.